Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Taysha Gene Therapies (TSHA – Research Report) and Zimmer Biomet Holdings (ZBH – Research Report).
Taysha Gene Therapies (TSHA)
In a report released today, Gil Blum from Needham reiterated a Buy rating on Taysha Gene Therapies, with a price target of $7.00. The company’s shares closed last Thursday at $2.57.
According to TipRanks.com, Blum is a 3-star analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Taysha Gene Therapies with a $7.07 average price target.
See the top stocks recommended by analysts >>
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on TSHA:
- Cantor Fitzgerald biotech analysts hold an analyst/industry conference call
- These 2 ‘Strong Buy’ Penny Stocks Could Rally to $9, Says Piper Sandler
- Apple upgraded, Tesla downgraded: Wall Street’s top analyst calls
- Neurogene initiated with an Outperform at Leerink
- Taysha Gene Therapies initiated with an Overweight at Piper Sandler
